Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Dow
Teva
Farmers Insurance
Moodys
Boehringer Ingelheim
McKinsey
US Department of Justice
Baxter

Generated: December 11, 2018

DrugPatentWatch Database Preview

PANRETIN Drug Profile

« Back to Dashboard

Which patents cover Panretin, and when can generic versions of Panretin launch?

Panretin is a drug marketed by Eisai Inc and is included in one NDA.

The generic ingredient in PANRETIN is alitretinoin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alitretinoin profile page.

Drug patent expirations by year for PANRETIN
Pharmacology for PANRETIN
Drug ClassRetinoid
Synonyms for PANRETIN
(2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
(2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid
(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(2E,4E,6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid
(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
(2E,4E.6Z,8E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexan-1-yl)-2,4,6,8-nonatetraenoic acid
(7E,9Z,11E,13E)-retinoic acid
(9cis)-retinoic acid
[3H]-9-cis-retinoic acid
[3H]9-cis-retinoic acid
15-Apo-beta-caroten-15-oate
1UA8E65KDZ
2,4,6,8-Nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (2E,4E,6Z,8E)-
300R038
42156-EP2295426A1
42156-EP2295427A1
42156-EP2311808A1
42156-EP2311829A1
42156-EP2311840A1
5300-03-8
9 Cis Retinoic Acid
9-(Z)-retinoic Acid
9-cis RA
9-cis Retinoic Acid
9-cis-RA
9-cis-Retinoate
9-CIS-RETINOIC ACID
9-CIS-RETINOIC ACID (SEE RETINOID PROJECT 6)
9-cis-Retinoic acid, >=98% (HPLC)
9-cis-Tretinoin
9-CRA
9-Retinoate
9-Retinoic acid
9(Z)-Retinoic acid
9C-RA
9CRA
AC1L9MT9
Acid, Retinoic
Acid, trans-Retinoic
Acid, Vitamin A
AGN 192013
AGN-192013
AJ-63024
AK116699
AKOS005622553
Alitretinoin
Alitretinoin (USAN)
Alitretinoin [USAN:INN:BAN]
Alitretinoin [USAN]
Alitretinoin|||Retinoid analogues
alitretinoina
alitretinoine
alitretinoinum
all-trans- Vitamin A1 acid
All-trans-b-retinoate
All-trans-beta-retinoate
alpha-acido (argentina)
alpha-vitaminsyre [denmark]
ALRT 1057
ALRT-1057
ALRT1057
Atragen
B-retinoate
BAL-4079
BAL4079
BB 0261656
BB_NC-1005
BDBM31892
beta-Retinoate
BML2-E06
BRD-K35483542-001-02-3
BSPBio_001495
C15493
CAS-5300-03-8
CCG-208266
CCRIS 7098
CHEBI:50648
CHEMBL705
D02815
D09RQU
D0G3PI
D0Y3LW
DB00523
DSSTox_CID_20404
DSSTox_GSID_40404
DSSTox_RID_79490
DTXSID6040404
GTPL2645
GTPL5383
HMS1361K17
HMS1791K17
HMS1989K17
HMS3402K17
HSDB 7186
IDI1_033965
Isotretinoin retinoate
Isotretinoin Retinoic acid
LG-100057
LG100057
LGD 100057
LGD 1057
LGD-1057
LGD1057
LMPR01090022
LP000986
LS-1328
MFCD00270072
MolPort-002-507-281
NCGC00161590-01
NCGC00161590-02
NCGC00161590-03
NCGC00161590-04
NCGC00161590-05
NCGC00161590-06
NCGC00161590-07
NCGC00255697-01
NSC 659772
NSC-659772
NSC659772
Panretin (TN)
Panretin Gel
Panretyn
Panrexin
Retin A (TN)
Retinoic acid, 9-cis-
Retinoic acid, cis-9,trans-13-
Retinova
Retisol-A
Ro-04-4079
Salt, Tretinoin Zinc
SCHEMBL18666
SHGAZHPCJJPHSC-ZVCIMWCZSA-N
Spectrum5_001935
SR-05000013784
SR-05000013784-1
STK801887
STOCK1N-38565
Toctino
Tox21_302195
trans Retinoic Acid
trans-Retinoate
trans-Vitamin a acid
Tretinoin (JAN/USP)
Tretinoin (TN)
Tretinoin [USAN:BAN:INN]
Tretinoin Zinc Salt
Tretinoin/all-trans retinoate
Tretinoina
Tretinoinum
Tri-Luma
UNII-1UA8E65KDZ
UPCMLD-DP097:001
UPCMLD-DP097:002
W-200595
Zinc Salt, Tretinoin
ZINC12661824

US Patents and Regulatory Information for PANRETIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc PANRETIN alitretinoin GEL;TOPICAL 020886-001 Feb 2, 1999 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for PANRETIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc PANRETIN alitretinoin GEL;TOPICAL 020886-001 Feb 2, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Eisai Inc PANRETIN alitretinoin GEL;TOPICAL 020886-001 Feb 2, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Citi
Merck
Cantor Fitzgerald
US Department of Justice
Boehringer Ingelheim
Federal Trade Commission
AstraZeneca
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.